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Objectives: To obtain Western European perspectives on the economic burden of atherothrombosis in
patients with multiple risk factors only (MRF), cerebrovascular disease (CVD), coronary artery disease
(CAD), and in the under-evaluated group of patients with peripheral arterial disease (PAD), we examined
vascular-related hospitalisation rates and associated costs in France and Germany.
Design: The prospective REACH Registry enrolled 4693 patients in France, and 5594 patients in Germany
(from December 2003 until June 2004).
Methods: For each country, 2-year rates and costs associated with cardiovascular events and vascular-
related hospitalisations were examined for patients with MRF, CVD, CAD, and PAD.
Results: Two-year hospitalisation costs were highest for patients with PAD (3182.1V for France; 2724.4V
for Germany) and lowest for the MRF group (749.1V for France; 503.3V for Germany). Peripheral
revascularizations and amputations were the greatest contributors to costs for all risk groups. Across all
PAD subgroups, peripheral procedures constituted approximately half of the 2-year costs.
Conclusion: Hospitalisation rates and costs associated with atherothrombotic disease in France and
Germany are high, especially so for patients with PAD.
 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
The burden of atherothrombotic disease is growing and is
among the world’s largest health problems.1 Future projections
suggest that this trend may further continue in Western countries
due to the ageing of the population and the increased adoption ofEconomics and Technology
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Magnuson).
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ciety for Vascular Surgery. Publisheunhealthy lifestyles and their clinical sequelae.1 The impact of this
trend will be felt at the individual level, and will pose further
economic challenges to nations’ health care systems.2
Parallel to coordinated preventive efforts in Europe,3 there is
a need to monitor the current burden of atherothrombosis, both in
terms of mortality and morbidity, its economic burden, and to
identify subgroups of atherothrombotic conditions at high risk of
morbidity/mortality and/or expenditures. Despite declining death
rates due to atherothrombosis,2,4 a large group of individuals are
living with the consequences of the disease with substantial
morbidity.2 Limitations of available information relating to the
economic burden of atherothrombosis in Europe include older
data,4,5 a potential under-estimation of true event rates by ofﬁciald by Elsevier Ltd. All rights reserved.
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Europe-wide atherothrombotic disease morbidity data.2
The REduction of Atherothrombosis for Continued Health
(REACH) Registry, a global real-world prospective registry, was
designed to capture recent trends in atherothrombotic disease
burden.3 Data were collected on patients with established cere-
brovascular (CVD), coronary (CAD), peripheral arterial disease
(PAD), and combinations thereof, as well on patients without
established disease, but presenting with minimum 3 athero-
thrombotic risk factors.3,4 Previous reports from REACH on the
economic burden of atherothrombosis in the US5 and Canada6
revealed a high degree of morbidity, mortality, and high associ-
ated cost, in patients at risk of atherothrombosis, particularly for
patients with PAD and/or polyvascular disease.6,7 The aims of the
current study were to provide a Western European perspective
through a detailed examination of vascular-related hospitalisation
rates and associated costs in REACH patients enrolled in France and
Germany fromDecember 2003 until June 2004, using 1-year and 2-
year follow-up data. Outcomes will be examined stratiﬁed
according to speciﬁc affected arterial beds, and anticipating the
particularly high disease and economic burden for patients with
PAD,4,5 we additionally aim to present average 1-year and 2-year
vascular-related hospitalisation costs associated broken-down by
PAD group (claudication, revascularisation, and amputation) by
country.
Methods
Participants and study design
The methodology for the overall REACH Registry has been
described in detail in prior work.3,6,8 A total of 4693 patients were
enrolled from France and 5594 patients from Germany between
December 2003 and June 2004. In Germany, patients were enrolled
from 713 outpatient treatment centres; in France patients were
enrolled from 509 outpatient centres. The distribution of practice
types and geographic regions for each country are presented in
Appendix I. To ensure consecutive enrolment and maximise gen-
eralisability, ofﬁces were not allowed to enrol for more than 5 days
from time of ﬁrst enrolment until last enrolment.
Patients were eligible for inclusion if they were aged 45 years,
and if at least one of the following criteria were met: (1) the
presence of any combination of 3 or more atherothrombotic risk
factors [male 65 years, female 70 years, diabetes mellitus, dia-
betic nephropathy, hypertension, hypercholesterolaemia, current
smoking, asymptomatic ankle-brachial index (ABI) <0.90, asymp-
tomatic carotid stenosis 70%, and presence of 1 carotid plaque];
(2) documented CVD, including a transient ischaemic attack and/or
stroke; (3) a documented history of established CAD [stable angina,
unstable angina, myocardial infarction, angioplasty/stenting, coro-
nary artery bypass grafting]; (4) documented symptomatic PAD [a
history of current intermittent claudication with either an ABI
<0.90, peripheral angioplasty/stenting/bypass graft, or amputa-
tion]. The protocol was approved at the designated local institu-
tional review board for each enrolling centre and all enrolled
patients provided written informed consent.
Data collection
Follow-up events
Major cardiovascular events and hospitalisations for vascular-
related reasons and vascular procedures were documented at 1-
year and 2-year follow-up visits starting from patients’ enrolment
in 2004 by physicians at each enrolling centre.3 Events were not
adjudicated; however, reports of ischaemic stroke and transientischaemic attack had to be documented from a neurologist or
hospital report to establish a reliable diagnosis.
Site visits were carried out to ensure data quality; 10% of all sites
in each country that enrolled at least 1 patient were subject to
a data audit. Six percent of sites to be audited were selected
randomly and another 4% of sites were audited based on the
number of queries and degree of missing data observed from the
site. At all the sites that underwent monitoring, all case report
forms for patients enrolled at each site were monitored for source
documentation and accuracy.3
Hospitalisation costs
Hospitalisations associated with cardiovascular events and
vascular-related procedures were documented in all patients. Each
reported hospitalisation was assigned to a US diagnosis-related
group (DRG) category according to the primary diagnosis and
procedures (if any) performed. For each country, a mapping to the
country-speciﬁc DRGswas performed by local experts, and national
costs estimates for each hospitalisation typewere provided. All cost
estimates were expressed in Euros (V) pertaining to the year of
enrolment (2004). For DRGs for which mapping was impossible,
a conversion method was used whereby an average conversion
factor was computed comparing the US cost per DRG to the local
cost per DRG for all DRGs with a correct mapping. This conversion
factor was then applied to all DRGs with no mapping.9
The primary data sources to derive cost information from in
France were the unit costs presented by the Agence Technique de
l’Information sur l’Hospitalisation.10,11 These data sources were
complemented by speciﬁc cost per inpatient stay calculations for
stroke, to obtain a more accurate cost estimate by differentiating
transient ischaemic attacks (TIAs) from haemorrhagic and ischae-
mic strokes. The National Discharge Abstract Data Base provided
rates at which DRG-speciﬁc hospitalisations occurred at private and
public hospitals; this information was used to calculate a weighted
average cost. In Germany, costs per DRG were derived from the
German 2004 Case Fees Catalogue.12 (Appendix II.)
Statistical analysis
For each country, baseline characteristics andmedication use, 2-
year rates of major cardiovascular events (cardiovascular death, MI,
or stroke), average cumulative 2-year vascular-related hospital-
isation rates per 1000 patients and associated average 1-year and 2-
year hospitalisation costs per patient were summarised according
to 4 risk categories: patients withmultiple risk factors only, patients
with any established CVD, any CAD, and any PAD at baseline.
The 2-year hospitalisation rates and associated cost estimates
were based on patients (n ¼ 4294 [91.5%] for France; n ¼ 4806
[85.9%] for Germany who completed all follow-up visits as well as
on patients who were reported to have died during follow-up).
Rates of cardiovascular death and hospitalisations involving fatal
events were based on all patients who had any follow-up visit
(n ¼ 4557 [97.1%] for France; n ¼ 5326 [95.2%] for Germany).
Multivariable Poisson regression was used to evaluate the effect
of baseline established vascular disease status and other covariates
on the overall 2-year hospitalisation rate, and to derive adjusted 2-
year hospitalisation rate estimates associated with for different risk
groups within each country. Covariates included age, gender, dia-
betes mellitus, hypertension, history of hypercholesterolaemia,
waist obesity, current and prior smoking, serum creatinine (mg/dL),
fasting blood glucose (mg/dL), fasting total cholesterol (mg/dL),
fasting triglycerides (mg/dL), and systolic blood pressure (mmHg).
Note that since CVD, CAD, and PAD categories were not mutually
exclusive, we compared each clinical category against all patients
who were not in that category.
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by indices of severity, cumulative 1-year and 2-year costs associ-
ated with hospitalisations for vascular reasons were analysed per
country for the following groups of patients with symptomatic
PAD: (1) patients with intermittent claudication but who had no
history of peripheral revascularisations at baseline, (2) patients
with a history of peripheral revascularisation [angioplasty/stent-
ing/bypass graft], or (3) patients who had undergone a lower limb
amputation prior to inclusion in the REACH study.
All analyses were conducted with SAS Version 9.1.3 (SAS Insti-
tute, Cary, NC) and tests for signiﬁcance were 2-tailed with alpha
levels of 0.05.
Results
Risk proﬁle and baseline characteristics of REACH patients for France
and Germany
The majority of patients in both countries had either CAD
without other arterial sites being affected (40% in both countries) at
baseline, or had multiple risk factors only (25% in France and 11% in
Germany). Overall, 13% and 25% had established polyvascular
disease (2 arterial sites affected), for France and Germany,
respectively (Fig. 1).
The average age range for both countries across risk groups was
68e72 years (Table 1). The majority were male. A history of dia-
betes was highest for patients withmultiple risk factors only (64.0%
for France; 73.4% for Germany), and ranged for the other risk groups
from 29% to 34% for France and from 42% to 46% for Germany. A
history of, hypertension, hypercholesterolaemia, obesity, and
intake of tobacco was high among all risk groups, with patients
from Germany tending to have higher rates of hypertension and
obesity. The majority of patients were on a statin at enrolment
(58e79%), and there was a wide variation in the use of antiplatelets
(e.g., 32e73% for aspirin, with aspirin being mostly prescribed in
patients with any CAD). Among patients with PAD, claudication
medication use upon enrolment was considerably higher for
patients enrolled in France (49% vs. 18%).
Two-year cardiovascular events, hospitalisation rates, and
associated costs
The highest 2-year cardiovascular event rates (%) for the
combined endpoint of cardiovascular death/myocardial infarction/
stroke/cardiovascular rehospitalisation were noted for patients
with any PAD in both countries (24.3% for France; 27.9% for Ger-
many), followed by patients with any CAD (17.9% for France; 20.9%Figure 1. REACH Registry: Risk Proﬁle of France and Germany. Abbreviations: CAD, coronary
cerebrovascular disease; TIA, transient ischaemic attack; PAD, peripheral arterial disease.for Germany), and any CVD (15.7% for France; 21.1% for Germany)
(Table 2). Patients with multiple risk factors only had the lowest
event rates (6.4% for France; 9.7% for Germany).
Two-year rates of hospitalisations per 1000 patients, classiﬁed
for the purpose of DRG assignment into those involving and those
not involving vascular procedures (as it is often the procedure that
determines DRG assignment and associated cost), are also pre-
sented in Table 2. Of note, some of the hospitalisations that involved
a revascularisation (e.g., percutaneous coronary intervention/
stenting) also included a clinical event (e.g., unstable angina/
myocardial infarction). Hospitalisations that involved vascular
interventions typically involved interventions in the vascular
segment that deﬁned the patient groups at inclusion (i.e., carotid
interventions tended to occur in patients with CVD; coronary
interventions in patients with CAD, and peripheral interventions in
patients with PAD).
Average cumulative 1-year and 2-year costs (per patient)
associated with hospitalisations for vascular reasons are presented
separately for France and Germany in Fig. 2. A similar pattern of
costs across risk groups is seen for both countries: cost burden was
highest for patients with any PAD, and the largest contribution to
those costs came from peripheral interventions. Peripheral inter-
ventions and coronary revascularisations rank among the top
contributors to these costs for both countries, followed by non-
fatal stroke/TIA for patients with any CVD (both in France and
Germany), fatal MI/fatal stroke/other cardiovascular death for
patients with any CAD in France, and non-fatal MI/unstable
angina/other ischaemic events for patients with any CAD in
Germany.
Model-based estimates of 2-year vascular-related hospital-
isation rates and associated 95% conﬁdence intervals, adjusted
for baseline clinical and demographic characteristics, are pre-
sented in Fig. 3. Results from the Poisson regression models upon
which these adjusted hospitalisation rates are based are pre-
sented in Appendix III. Baseline variables associated with
signiﬁcantly increased hospitalisation rates for both countries
include diabetes, both prior and current smoking, and increasing
fasting triglyceride levels. After adjusting for both baseline
factors and the presence of disease in other arterial beds,
established PAD was associated with a greater than 2-fold
increase in the rate of hospitalisation. The presence (vs.
absence) of established CAD and CVD were each associated with
signiﬁcant increases in the hospitalisation rate, though the
magnitude of those effects was lower than for PAD. Patients with
multiple risk factors only were signiﬁcantly less likely to be
hospitalised at 2-year follow-up, as compared with patients with
established vascular disease.artery disease; MI, myocardial infarction; CABG, coronary artery bypass grafting; CVD,
Table 1
Baseline Characteristics for REACH Patients in France and Germany. Characteristics are presented by patients with multiple risk factors only and by affected arterial bed.a
France Germany
Multiple Risk
Factors Only
Any CVD Any CAD Any PAD Multiple Risk
Factors Only
Any CVD Any CAD Any PAD
(n ¼ 1179) (n ¼ 821) (n ¼ 2473) (n ¼ 923) (n ¼ 608) (n ¼ 1706) (n ¼ 3510) (n ¼ 1354)
Demographics, %
Age, years, mean (SD) 70.2 (9.0) 71.7 (10.1) 69.1 (10.2) 69.3 (10.6) 68.4 (9.1) 69.4 (9.1) 68.0 (9.0) 68.0 (8.9)
Men 58.8 69.4 78.3 81.4 51.0 62.4 73.6 71.5
Socioeconomic factors, %
<High school 79.6 77.5 73.5 77.3 82.9 81.3 79.1 84.4
Non-active working status 84.1 89.6 86.8 86.5 85.3 92.2 87.4 89.3
Medical history, %
Diabetes mellitusb 64.0 29.4 32.2 33.8 73.4 42.3 42.1 45.6
Hypertensionc 89.5 80.4 69.8 73.0 93.4 89.6 90 85.9
Hypercholesterolaemia 78.6 65.3 79.6 69.8 66.7 65.3 80 68.4
Obesityd 61.8 44.0 46 40.9 68.5 54.4 51.7 50.0
Former smoker 29.7 44.3 49.5 54.6 23.8 40.7 47.2 46.5
Current smoker 18.3 9.7 12.6 22.0 20.2 15.1 12.6 27.3
Baseline medication use, %
Antiplatelet agents
Aspirin 31.5 49.1 66 42.3 41.6 59.5 73.3 68.7
Other 7.5 36.5 33.7 45.8 4.3 35.0 24.4 24.5
Oral anticoagulants 7.0 21.2 12.9 15.2 6.3 14.9 13.2 14.9
Statins 59.9 58.0 77.6 62.7 57.8 62.0 79.1 66.9
Calcium channel blockers 33.8 34.1 38.1 38.1 30.2 32.4 27.6 31.7
Beta-blockers 30.6 34.4 60.3 30.1 44.5 51.7 75.3 53.2
Nitrates/other anti-anginal drugs 3.5 16.8 39.4 22.8 5.3 20.3 34.3 23.3
Diuretics 53.5 50.2 37.1 44.2 49.7 49.3 50.4 49.4
Angiotensin-converting enzyme inhibitors 39.4 41.4 42.8 37.0 51.1 54.7 61.3 55.8
Angiotensin II receptor blockers 31.2 25.1 17 21.1 29.3 19.6 19.6 18.7
Other anti-hypertensives 14.2 10.7 6.8 10.0 13.8 12.3 9.5 9.4
Claudication medicationse 5.2 11.7 11.3 48.9 2.2 8.2 5.3 17.5
Diabetic agentsf 62.5 27.5 29.9 32.1 65.5 36.0 34.6 38.3
Pluseminus values represent means  standard deviation.
Abbreviations: CVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral arterial disease.
a Note that categories are not mutually exclusive.
b Type 1 or 2 diabetes mellitus currently treated with hypoglycemic agents, or history of diabetes.
c Patients currently treated with medication.
d Men: waist circumference of 102 cm or more; women: waist circumference of 88 cm or more.
e Claudication medications included cilostazol, pentoxifylline, buﬂomedil, naftidrofuryl, and ginkgo biloba.
f Diabetic agents included biguanides, agonists and other antidiabetic agents [including glucosidase inhibitors, meglitinides, .].
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Cumulative 1-year and 2-year hospitalisation costs per patient,
for patients with established PAD at baseline, are presented in Fig. 4
for different PAD subgroups (patients with intermittent claudica-
tion, patients with a history of revascularisation, and patients who
had a history of amputation upon enrolment). Across all PAD
subgroups, peripheral revascularisations [either peripheral bypass
grafting, peripheral angioplasty/stenting, or lower limb amputa-
tion] constituted roughly half of both the 1-year and 2-year costs,
followed by costs associated with CAD and/or coronary interven-
tions. Average per patient costs were particularly high for the
amputation group for France (3559V in year 1, 6016V in year 2);
costs were similar across PAD subgroups for Germany (range
1005Ve1516V for year 1; 2404Ve2720V for year 2).
Discussion
The current study is the ﬁrst to provide a detailed overview of
the health economic burden associated with the spectrum of
atherothrombotic disease in Western European countries such as
France and Germany. Parallel data from two European countries
conﬁrm the high cost associated with vascular-related hospital-
isations in this region, and reveal the especially high rates of
rehospitalisation and associated costs for patients with PAD, largely
attributed to vascular interventions and major cardiovascular
events. Roughly half of the hospitalisation costs for patients withestablished PAD at baseline were associated with PAD-related
interventions, even in patients with only symptoms of intermit-
tent claudication (and no prior history of revascularisation). The
particularly high economic burden for PAD relative to CAD or CVD,
has also been observed in other countries including the US and
Canada.5,6,13 To place these costs further in perspective, average
annual costs associated with vascular-related hospitalisations for
the patient subgroups examined in our study are of equal magni-
tude, if not greater than estimates of hospital costs associated with
Type II diabetes mellitus (most recent estimates of annual direct
costs for Type II diabetes per patient for in-hospital care range from
V1540 in France to V1878eV2173 in Germany).14,15 As the REACH
Registry focused only upon hospitalisations and events that were
related to vascular disease, the annual hospitalisation cost esti-
mates from this study underestimate (and were not construed to
represent) overall hospitalisation costs in REACH patients.
Despite the recognition that atherothrombotic disease will
continue to be one of the largest health problems in the upcoming 2
decades,16,17 challenging European health care delivery systems at
both the local and national level, estimates of the economic impact
have not been readily available in literature.17,18 Although a prior
report on overall expenditures associated with ischaemic heart
disease and CVD in Europe18 provided aggregated costs for inpa-
tient care, it was unable to attribute different types of costs to
speciﬁc diagnoses or procedures associated with the hospital-
isation. These data from REACH reveal that the majority of costs can
be attributed to vascular interventions for peripheral, carotid or
Table 2
Percent of Patients Experiencing at Least 1 Cardiovascular Event at 2 Years and Cumulative 2-Year Rates of Hospitalisations per 1000 Patients, by Involved Vascular Disease
Sites.
Clinical Reason for Hospitalisation France Germany
Multiple Risk
Factors Only
Any CVD Any CAD Any PAD Multiple Risk
Factors Only
Any CVD Any CAD Any PAD
(n ¼ 1157) (n ¼ 789) (n ¼ 2397) (n ¼ 882) (n ¼ 588) (n ¼ 1604) (n ¼ 3328) (n ¼ 1303)
Cardiovascular events, %
CV death 0.9 2.5 3.3 4.1 2.0 3.5 2.9 3.6
CV death/MI/Stroke 2.7 7.5 6.0 5.9 3.4 9.0 5.9 7.7
CV death/MI/Stroke/Hospitalisation 6.4 15.7 17.9 24.3 9.7 21.1 20.9 27.9
Hospitalisations involving vascular interventions, event rates per 1000 patients
CABG 5.5 6.7 8.4 8.5 1.8 19.9 27.8 24.9
PCI/Stenting 15.7 24.1 55 32.6 14.7 34.9 84.7 65.1
Carotid Surgery 3.7 16.1 7.1 10.9 3.7 15.0 6 12.9
Carotid Angioplasty/Stenting 4.6 6.7 4 3.6 1.8 15.7 7.6 14.6
Lower Limb Amputation 2.8 14.8 6.2 27.8 3.7 7.8 6 19.7
Peripheral Angioplasty/Stenting 12.0 8.0 24 84.5 18.4 50.6 44.7 167.1
Peripheral Bypass Graft 5.5 6.7 14.6 56.8 1.8 11.4 19.9 66.8
Hospitalisations involving no vascular interventions, event rates per 1000 patients
Non-fatal events
Non-fatal Stroke 20.3 65.7 24 10.9 11.1 69.8 29.5 37.7
Non-fatal MI 12.0 10.7 20.4 24.2 5.5 12.8 17.5 19.7
PAD e New Diagnosis 1.8 5.4 4 1.2 5.5 4.3 3.6 0
Worsening of Claudication 11.1 17.4 22.2 101.5 5.5 32.8 27.5 96.8
Unstable Angina 4.6 12.1 49.2 26.6 12.9 47.0 102.3 75.4
TIA 6.5 24.1 8.4 8.5 7.4 45.6 17.2 26.6
Other Ischaemic Event 11.1 17.4 17.7 73.7 5.5 24.9 16.9 42.0
CHF 13.8 38.9 46.1 62.8 35.0 58.4 64.2 42.8
Bleeding with Transfusion 4.6 5.4 5.8 8.5 0 12.1 10.6 11.1
Fatal events
Fatal MI 1.7 2.5 6.7 6.8 1.7 7.5 7.8 9.2
Fatal Stroke 2.6 3.8 3.3 5.7 5.1 9.4 4.5 5.4
Other CV Death 4.3 19.1 23.4 28.3 13.6 18.1 17.1 21.5
Abbreviations: CVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral arterial disease; CABG, coronary artery bypass graft; PCI, percutaneous coronary
intervention; MI, myocardial infarction; CV, cardiovascular; TIA, transient ischaemic attack; CHF, chronic heart failure.
K.G. Smolderen et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 198e207202coronary artery disease. The high rates of interventional procedures
reported in our study have also been reported in studies examining
the adoption of newer revascularisation strategies for the treat-
ment of atherosclerosis.19,20 Prior reports revealed that a substan-
tial proportion of the variation in the use of these cardiovascular
interventions is at the hospital and geographical region level.21
Future studies aimed at identifying the optimal indications for€0
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to assist health care systems with the challenging task of insuring
the most efﬁcient allocation of limited health care funds.
The current study identiﬁes patients with PAD as a particularly
vulnerable group, with disproportionate rates of morbidity,
mortality, and high associated hospitalisation costs, not only the
ﬁrst year under study, but also the year thereafter. Multivariable€0
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teristics on the vascular hospitalisation rate for both France and
Germany, including diabetes, prior and current smoking status, and
increased triglyceride levels, and after adjustment for these effects
as well as the impact of established disease in other vascular beds,
a highly signiﬁcant two-fold increase in the rate of vascular-related
hospitalisation for patients with PAD was found, for both countries.
The high hospitalisation costs for patient with PAD are largely due
to the very high rate of peripheral revascularization procedures
performed, including repeat procedures, in this population. PAD is
undertreated and under recognised,7 despite the fact that it shares
the same underlying atherosclerotic process and risk factors as CAD
and CVD.22 Due in part to this undertreatment,23 as well as the fact€0
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Figure 4. Average Cumulative 1-Year and 2-Year Vascular-Related Hospitalisation Costs (V
Disease at Baseline, by PAD subgroup, for France and Germany. Abbreviations: CLAUD, inter
arterial disease; CVD, cerebrovascular disease; CHF, chronic heart failure.that patients with PAD tend to have atherosclerotic disease in other
arterial beds as well, patients with PAD are at an especially high risk
of cardiovascular events.4
A direct comparison of costs between France and Germany was
not a primary objective of this analysis; it is possible that different
referral policies and other practice patterns within the two coun-
tries may have impacted the costs, especially with respect to the
use of interventional procedures. Speciﬁc information regarding
referral and practice patterns at the site or country level was not
collected in REACH. Unit costs are different across countries and
may partly explain the relative difference in nominal cost levels
between France and Germany. However, the relative magnitude of
cost estimates across the vascular-bed categories tended to be€0
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Appendix I. Distribution of Types of Enrolment Centres and
Geographic Regions From Which Patients Were Enrolled Per
Country.
Practice Types per Country (%).
Practice Type France Germany
Private ofﬁce only 84.6 93.6
Public hospital only 8.9 1.0
Private hospital only 0.8 0.0
Multiple or other structure 5.7 5.4
Geographic Regions per Country (%).
Geographic Region France Germany
Urban only 60.7 69.6
Suburban only 26.2 7.1
Rural only 12.4 22.6
Multiple locations 0.6 0.6
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inﬂuence of speciﬁc medications and the achievement of speciﬁc
treatment targets on the clinical and economic outcomes of
patients in REACH from France and Germany was beyond the scope
of this analysis. Other reports have examined adherence to guide-
lines for risk factor management and its association with outcomes
using REACH data from Europe24 and for patients with PAD
speciﬁcally.25
Our ﬁndings should also be interpreted against the following
limitations. Neither outpatient care nor chronic care such as
nursing home or rehabilitation stays following stroke or amputa-
tionwere collected in REACH; in addition, our cost estimates do not
include costs associated with informal caregiving on the part of
patients’ familymembers or indirect costs associated lost time from
work. Only a small minority (10e15%) of patients in this study had
an active working status at baseline, and prior studies have shown
that the highest proportion of direct costs in this patient population
is related to in-hospital care.18 In addition, REACH did not capture
data relating to certain cardiac conditions (e.g., arrhythmia
management), or hospitalisations for non-cardiovascular condi-
tions. Also, these data, from 2004 to 2006, do not account for more
recent developments and adoption of endovascular treatment
approaches. Finally, as we only presented cost information for
France and Germany, these ﬁndings do not necessarily translate to
other surrounding countries in Western Europe.
Despite these potential limitations, the current report provides
unique insight into the economic burden of atherothrombosis from
the perspective of 2 large Western European countries. From the
health policy perspective, atherothrombosis and peripheral arterial
disease will continue to exert tremendous pressure on public
health care resources over the next quarter century. The cost esti-
mates provided herein have potential usefulness as inputs into
health economic models aimed at examining the cost implications
and cost-effectiveness of different treatment options for patient at
risk of atherothrombosis and/or with PAD. As the majority of costs
were associated with interventional procedures, future outcomes
research may need to be directed towards identifying the optimalAppendix II. Unit Costs and Source Information for Derived Costs
Hospitalisation Costs for France e REACH Registry
Principal Diagnosis Procedure
Hospitalisations with procedure
any amputation affecting lower limbs
any CABG
any CABG & coronary angioplasty/ste
any carotid angioplasty/stenting
any carotid surgery
any other interventions for PAD
(angioplasty/stenting)
any peripheral bypass graft
Non-fatal MI coronary angioplasty/stenting
Unstable Angina coronary angioplasty/stenting
Other ischaemic arterial event coronary angioplasty/stenting
Congestive heart failure coronary angioplasty/stenting
No clinical outcomes leading to hosp. reported coronary angioplasty/stenting
Hospitalisations without procedure
Fatal MI none
Fatal Stroke none
Other CV death none
Stroke e Ischaemic noneuse of these interventions from both a clinical and cost-
effectiveness perspective, to assist health policy makers to priori-
tise future health care expenditures. Importantly, our data repre-
sent a special call to action with regard to patients living with PAD
and its consequences. Future efforts to advance knowledge,
improve quality of care, and control costs associated with the
treatment of atherothrombotic disease in general e and in patients
with PAD in particular should include facilitation of quality of care
initiatives that focus on improved cardiovascular risk factor control,
as well as the monitoring of the impact of such programs on
outcomes, and the evaluation cost-effectiveness.per Country.
US DRG US Total Costa French Cost
113 $22,077 11,311V
107/109 $37,094 15,202V
nting 106 $53,633 17,626V
533/534 $10,950 5704 V
533/534 $10,950 5704 V
478/479 $18,518 10,735V
478/479 $18,518 10,735V
516/526 $23,488 5987V
516/526/518 $20,912 4531V
516/526/518 $20,912 4531V
517/527/518 $18,943 4525V
517/527/518 $18,943 4525V
123 $11,300 4216V
014 $9818 4385V
174,175,099,100,325,326,
046,047,066,144,145,127,
129,138
$8127 7742V
014 $9818 4385V
Appendix (continued)
Hospitalisation Costs for France e REACH Registry
Principal Diagnosis Procedure US DRG US Total Costa French Cost
Stroke e hemorrhagic none 014 $9818 4385V
Hospitalisations with procedure
Stroke e unknown origin none 014 $9818 4385V
Non-fatal MI none 121/122 $11,103 4415V
Peripheral Artery Disease e new diagnosis none 130/131 $7403 900V
Worsening of claudication related to PAD none 130/131 $7403 900V
Unstable Angina none 140 $4896 2209V
TIA none 524 $6898 2521V
Other ischaemic arterial event none 132/133 $5671 1169V
Congestive heart failure none 127 $8115 4117V
Episode of bleeding w/transfusion none 174,175,099,100,325,326,046,
047,066,144,145
$8550 2908V
aMedPAR 2004 hospital costs plus associated
physician costs estimated based on Mitchell JB,
Burge RT, Lee AJ, et al. Per Case Prospective
Payment for Episodes of Hospital Care.
Springﬁeld, Va: US Dept of Commerce
National Technical Information Service;
Publication PB95226023
Sources for French cost: A partir des arbres GHM
de Charisma
GHM 186: arrêt
cardiaque
Répartition des
GHM pour
amputation: 161, 162
Hospitalisation Costs for Germany e REACH Registry
Principal Diagnosis Procedure US DRG US Total Costa German DRG Local Cost
Hospitalisations with procedure
any amputation affecting lower limbs 113 $22,077 F28A,F28B V 7690
any CABG 107,109 $37,094 F05B,F06B V 11,688
any CABG & coronary
angioplasty/stenting
106 $53,633 F05A,F06A V 13,924
any carotid angioplasty/stenting 533,534 $10,950 B04A,B04B V 5061
any carotid surgery 533,534 $10,950 B04A,B04B V 5061
any other interventions for PAD
(angioplasty/stenting)
478,479 $18,518 F15A,F15B,F16Z,F10Z V 3676
any peripheral bypass graft 478,479 $18,518 F15A,F15B,F16Z,F10Z V 3676
Non-fatal MI coronary angioplasty/stenting 516,526 $23,488 F10Z V 5087
Unstable Angina coronary angioplasty/stenting 516,526,518 $20,912 F15B V 2996
Other ischaemic arterial event coronary angioplasty/stenting 516,526,518 $20,912 F15A,F15B,F16Z V 3205
Congestive heart failure coronary angioplasty/stenting 517,527,518 $18,943 F15A,F15B,F16Z V 3205
No clinical outcomes leading to
hospitalisation reported
coronary angioplasty/stenting 517,527,518 $18,943 F15A,F15B,F16Z,F10Z V 3676
Hospitalisations without procedure
Fatal MI none 123 $11,300 F60A,F60B V 3904
Fatal Stroke none 014 $9818 B70C V 3381
Other CV death none 174,175,099,100,325,
326,046,047,066,144,
145,127,129,138
$8127 G73A,G46A,G48A,
G73C,G46B,G48B,
E67A,E67B,L69A,
L65Z,C62Z,C63Z,
D62Z,F75A,F75B,F62C
V 3585
Stroke e Ischaemic none 014 $9818 B70A,B70B,B70C,B70D,B70E V 3078
Stroke e hemorrhagic none 014 $9818 B70A,B70B,B70C,B70D,B70E V 3078
Stroke e unknown origin none 014 $9818 B70A,B70B,B70C,B70D,B70E V 3078
Non-fatal MI none 121/122 $11,103 F60A,F60B V 3517
Hospitalisations with procedure
Peripheral Artery Disease e new diagnosis none 130/131 $7403 F63A,F63B V 2923
Worsening of claudication related to PAD none 130/131 $7403 F63A,F63B V 2923
Unstable Angina none 140 $4896 F72B V 1672
TIA none 524 $6898 B69A,B69B V 2555
Other ischaemic arterial event none 132/133 $5671 F66A,F66B V 2524
Congestive heart failure none 127 $8115 F62C V 2412
Episode of bleeding with transfusion none 174,175,099,100,
325,326,046,047,
066,144,145
$8550 G73A,G46A,G48A,G73C,G46B,
G48B,E67A,E67B,L69A,L65Z,
C62Z,C63Z,D62Z,F75A,F75B
V 2499
a MedPAR 2004 hospital costs plus associated physician costs estimated based on Mitchell JB, Burge RT, Lee AJ, et al. Per Case Prospective Payment for Episodes of Hospital
Care. Springﬁeld, Va: US Dept of Commerce National Technical Information Service; Publication PB95226023.
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Appendix III. Full Model Results from the Multivariable Poisson Regression Models (Part I) Used to Derive Adjusted Estimates of
the Inﬂuence of Different Vascular Disease Sites on 2-Year Vascular-Related Hospitalisation Rates for France and Germany (Part II).
France Germany
Parameter Coefﬁcient Standard Error Wald 95%
Conﬁdence
Intervals
P-value Coefﬁcient Standard Error Wald 95%
Conﬁdence
Intervals
P-value
Part I
Intercept 4.0325 0.3814 4.7800 3.2851 <0.0001 2.6781 0.2810 3.2288 2.1273 <0.0001
Multiple risk factors only 0.3782 0.1220 0.6172 0.1391 0.0019 0.7154 0.1334 0.9769 0.4539 <0.0001
Any CAD 0.5004 0.0794 0.3448 0.6559 <0.0001 0.2840 0.0587 0.1690 0.3990 <0.0001
Any CVD 0.1842 0.0840 0.0195 0.3488 0.0284 0.1451 0.0525 0.0422 0.2480 0.0057
Any PAD 0.7960 0.0695 0.6598 0.9322 <0.0001 0.7019 0.0502 0.6036 0.8002 <0.0001
Age 0.0057 0.0033 0.0008 0.0122 0.0849 0.0120 0.0028 0.0065 0.0175 <0.0001
Female 0.1300 0.0816 0.0299 0.2900 0.1111 0.1794 0.0534 0.0746 0.2841 0.0008
Diabetes 0.4706 0.0745 0.3245 0.6167 <0.0001 0.1534 0.0572 0.0414 0.2655 0.0073
Hypertension 0.0012 0.0744 0.1470 0.1447 0.9874 0.1072 0.0834 0.0563 0.2707 0.1987
History of hypercholesterolaemia 0.1886 0.0667 0.3194 0.0578 0.0047 0.0953 0.0554 0.0132 0.2038 0.0852
Waist obesity 0.1318 0.0620 0.2533 0.0103 0.0336 0.0633 0.0479 0.0306 0.1573 0.1864
Current smoking 0.4682 0.0962 0.2796 0.6568 <0.0001 0.1463 0.0741 0.0012 0.2914 0.0482
Prior smoking 0.3583 0.0759 0.2094 0.5071 <0.0001 0.1356 0.0542 0.0293 0.2419 0.0124
Serum Creatinine (mg/dl) 0.1346 0.0535 0.0298 0.2393 0.0118 0.0191 0.0467 0.0725 0.1107 0.6829
Fasting Blood Glucose (mg/dl) 0.0004 0.0009 0.0014 0.0022 0.6534 0.0031 0.0007 0.0018 0.0043 <0.0001
Fasting total cholesterol (mg/dl) 0.0019 0.0008 0.0004 0.0035 0.0156 0.0027 0.0006 0.0038 0.0016 <0.0001
Fasting triglycerides (mg/dl) 0.0015 0.0004 0.0008 0.0022 <0.0001 0.0010 0.0002 0.0005 0.0014 <0.0001
Systolic blood pressure 0.0061 0.0019 0.0023 0.0098 0.0014 0.0016 0.0012 0.0008 0.0040 0.1915
France Germany
RR Lower Upper RR Lower Upper
Part II
Multiple risk factors only 0.69 0.54 0.87 0.49 0.38 0.64
Any CVD 1.20 1.02 1.42 1.16 1.04 1.28
Any CAD 1.65 1.41 1.93 1.33 1.18 1.49
Any PAD 2.22 1.93 2.54 2.02 1.83 2.23
K.G. Smolderen et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 198e207206Conﬂict of Interest
 The REACH Registry was sponsored by Bristol-Myers Squibb
and sanoﬁ-aventis. The REACH Registry is endorsed by the
World Heart Federation. A complete list of REACH investigators
appears in JAMA 2006;295:180e9.
 The REACH Registry enforces a no ghost-writing policy. This
manuscript was written and edited by the authors, who take
full responsibility for its content. The ﬁrst draft was written by
Dr. Smolderen.
 Dr. Smolderen was supported by the Outcomes Research post-
doctoral fellowship awarded by the American Heart Associa-
tion Pharmaceutical Roundtable and David and Stevie Spina
[grant number AHA #: 0875149N] and by the Netherlands
Organization for Scientiﬁc Research [VENI grant no.:
916.11.179].
 Dr. Joachim Röther received honoraria for participation in
advisory boards and oral presentations from: Bayer Vital, BMS,
Boehringer-Ingelheim, Sanoﬁ-Aventis, Lundbeck
 Dr. de Pouvourville is receiving a honorarium as a member of
Sanoﬁ-Aventis Health Technology Assessment European board.
Dr. Brüggenjürgen has received honoraria from AstraZeneca,
Sanoﬁ-Aventis and The Medicines Company.
 Dr. Parhofer has received research grants and/or honoraria for
consulting or presentations from AstraZeneca, Boehringer-
Ingelheim, Bristol-Myers Squibb, Diamed, Fresenius Medical
Care, Genzyme, Kaneka, Merck Sharp & Dohme, Novartis,
Roche and Sanoﬁ.
 Dr. Steg has received research grant support from Servier
(2009e2014); is a consultant or advisory board member for
Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS,
Daiichi-Sankyo-Lilly, GlaxoSmithKline, Medtronic, Otsuka,Roche, sanoﬁ-aventis, Servier, and The Medicines Company,
and is a stockholder for Aterovax.
 Dr. Bhatt has received research support from AstraZeneca,
Bristol-Myers Squibb, Eisai, Sanoﬁ-Aventis, and The Medicines
Company.
 Dr. Magnuson has received grant support from Sanoﬁ-Aventis,
Bristol-Myers Squibb, Daiichi-Sankyo, and Eli Lilly, and has
received honoraria from sanoﬁ-aventis and Bristol-Myers
Squibb.
Role of the Funding Source
All manuscripts in the REACH Registry are prepared by inde-
pendent authors who are not governed by the funding sponsors
and are reviewed by an academic publications committee before
submission. The funding sponsors have the opportunity to review
manuscript submissions but do not have authority to change any
aspect of a manuscript.
References
1 Mathers CD, Loncar D. Projections of global mortality and burden of disease
from 2002 to 2030. PLoS Med 2006;3:e442.
2 Allender S, Scarborough P, Peto V, Rayner M, Leal J, Luengo-Fernandez R, et al.
European cardiovascular disease statistics. European Heart Network; 2008.
3 Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, et al. The REduction of
Atherothrombosis for Continued Health (REACH) Registry: an international,
prospective, observational investigation in subjects at risk for atherothrombotic
events-study design. Am Heart J 2006;151. pp. 786e781e786e710.
4 Steg PG, Bhatt DL, Wilson PW, D’Agostino R, Ohman EM, Rother J, et al. One-
year cardiovascular event rates in outpatients with atherothrombosis. JAMA
2007;297:1197e206.
5 Mahoney EM, Wang K, Cohen DJ, Hirsch AT, Alberts MJ, Eagle K, et al. One-year
costs in patients with a history of or at risk for atherothrombosis in the United
States. Circ Cardiovasc Qual Outcomes 2008;1:38e45.
K.G. Smolderen et al. / European Journal of Vascular and Endovascular Surgery 43 (2012) 198e207 2076 Smolderen KG, Bell A, Lei Y, Cohen EA, Steg PG, Bhatt DL, et al. One-year costs
associated with cardiovascular disease in Canada: insights from the REACH
Registry. Can J Cardiol 2010;26:297e305.
7 Hirsch AT, Criqui AT, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW,
et al. Peripheral arterial disease detection, awareness, and treatment in primary
care. JAMA 2001;286:1317e24.
8 Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda YA, Mas JL, et al. International
prevalence, recognition, and treatment of cardiovascular risk factors in outpa-
tients with atherothrombosis. JAMA 2006;295:180e9.
9 Schulman K, Burke J, Drummond M, Davies L, Carlsson P, Gruger J, et al.
Resource costing for multinational neurologic clinical trials: methods and
results. Health Econ 1998;7:629e38.
10 Echelle nationale des coûts et coûts de référence en euros par GHM. http://
www.atih.sante.fr/openﬁle.php?id¼448; 2003 [accessed 18.07.11].
11 Echelle privée de point ISAF par GHM. http://www.atih.sante.fr/openﬁle.php?
id¼443; 2001 [accessed 18.07.11].
12 Weiterentwicklung des G-DRG-Systems für das Jahr 2004, Band 2:
Fallpauschalen-Katalog, Klinische Proﬁle, Kostenproﬁle. http://www.g-drg.de/
cms/content/download/990/6530/version/2/ﬁle/Abschlussbericht_G-DRG_
V2004_0312191400_BII.pdf; 2003 [accessed 18.07.11].
13 Mahoney EM, Wang K, Keo HH, Duval S, Smolderen KG, Cohen DJ, et al. Vascular
hospitalization rates and costs in patients with peripheral artery disease in the
United States. Circ Cardiovasc Qual Outcomes 2010;3:642e51.
14 Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia
2002;45:S5e12.
15 Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes
mellitus: the evidence from Germanyethe CoDiM study. Diabetologia
2006;49:1498e504.
16 Escaned J, Rydén L, Zamorano JL, Poole-Wilson P, Fuster V, Gitt A, et al. Trends
and contexts in European cardiology practice for the next 15 years: the Madrid
declaration: a report from the European conference on the future of cardiology,
Madrid, 2e3 June 2006. Eur Heart J 2007;28:634e7.17 Tendera M. How much does Europe invest in the treatment of cardiovascular
diseases? Eur Heart J 2006;27:1521e2.
18 Leal J, Luengo-Fernandez R, Gray A, Petersen S, Rayner M. Economic burden of
cardiovascular diseases in the enlarged European Union. Eur Heart J 2006;27:
1610e9.
19 Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K,
et al. Heart disease and stroke statisticse2009 update: a report from the
American Heart Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation 2009;119:480e6.
20 Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower
extremity bypass surgery, endovascular interventions, and major amputations.
J Vasc Surg 2009;50:54e60.
21 Fox KA, Goodman SG, Anderson Jr FA, Granger CB, Moscucci M, Flather MD,
et al. From guidelines to clinical practice: the impact of hospital and
geographical characteristics on temporal trends in the management of acute
coronary syndromes. The Global Registry of Acute Coronary Events (GRACE).
Eur Heart J 2003;24:1414e24.
22 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-
society consensus for the Management of Peripheral Arterial Disease (TASC II).
J Vasc Surg Jan 2007;45(Suppl. S):S5e67.
23 McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors
are less intensively treated in patients with peripheral arterial disease
than in patients with coronary artery disease. J Gen Intern Med 1997;12:
209e15.
24 Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Röther J, et al.
Effects of adherence to guidelines for the control of major cardiovascular risk
factors on outcomes in the REduction of Atherothrombosis for Continued
Health (REACH) Registry Europe. Heart 2011;97:660e7.
25 Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, et al.
Cardiovascular risk factor control and outcomes in peripheral artery disease
patients in the REduction of Atherothrombosis for Continued Health (REACH)
Registry. Atherosclerosis 2009;204:e86e92.
